Can DKI-MRI predict recurrence and invasion of peritumoral zone of hepatocellular carcinoma after transcatheter arterial chemoembolization?

Xin Cao, Hao Shi, Wei-Qiang Dou, Xin-Yao Zhao, Ying-Xin Zheng, Ya-Ping Ge, Hai-Chao Cheng, Dao-Ying Geng, Jun-Ying Wang

Abstract

BACKGROUND
Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality worldwide. Transcatheter arterial chemoembolization (TACE) has been performed as a palliative treatment for patients with HCC. However, HCC is easy to recur after TACE. Magnetic resonance imaging (MRI) has clinical potential in evaluating the TACE treatment effect for patients with liver cancer. However, traditional MRI has some limitations.

AIM
To explore the clinical potential of diffusion kurtosis imaging (DKI) in predicting recurrence and cellular invasion of the peritumoral liver zone of HCC after TACE.
**METHODS**

Seventy-six patients with 82 HCC nodules were recruited in this study and underwent DKI after TACE. According to pathological examinations or the overall modified response evaluation criteria in solid tumors (mRECIST) criterion, 48 and 34 nodules were divided into true progression and pseudo-progression groups, respectively. The TACE-treated area, peritumoral liver zone, and far-tumoral zone were evaluated on DKI-derived metric maps. Non-parametric U test and receiver operating characteristic curve (ROC) analysis were used to evaluate the prediction performance of each DKI metric between the two groups. The independent t-test was used to compare each DKI metric between the peritumoral and far-tumoral zones of the true progression group.

**RESULTS**

DKI metrics, including mean diffusivity (MD), axial diffusivity (DA), radial diffusivity (DR), axial kurtosis (KA), and anisotropy fraction of kurtosis (Fak), showed statistically different values between the true progression and pseudo-progression groups ($P < 0.05$). Among these, MD, DA, and DR values were higher in pseudo-progression lesions than in true progression lesions, whereas KA and FAk values were higher in true progression lesions than in pseudo-progression lesions. Moreover, for the true progression group, the peritumoral zone showed significantly different DA, DR, KA, and FAk values from the far-tumoral zone. Furthermore, MD values of the liver parenchyma (peritumoral and far-tumoral zones) were significantly lower in the true progression group than in the pseudo-progression group ($P < 0.05$).

**CONCLUSION**

DKI has been demonstrated with robust performance in predicting the therapeutic response of HCC to TACE. Moreover, DKI might reveal cellular invasion of the peritumoral zone by molecular diffusion-restricted change.

**Key Words:** Diffusion kurtosis imaging; Hepatocellular carcinoma; Transcatheter arterial chemoembolization; Recurrence

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

---

**Core Tip:** This study demonstrated feasible performance and advantages of diffusion kurtosis imaging metrics (i.e., mean diffusivity, axial diffusivity, radial diffusivity, axial kurtosis, and anisotropy fraction of kurtosis) in evaluating liver cancer and tumoral cell invasion of peritumoral zone between hepatocellular carcinoma progressive group and pseudo-progressive group after transcatheter arterial chemoembolization treatment.

**Citation:** Cao X, Shi H, Dou WQ, Zhao XY, Zheng YX, Ge YP, Cheng HC, Geng DY, Wang JY. Can DKI-MRI predict recurrence and invasion of peritumoral zone of hepatocellular carcinoma after transcatheter arterial chemoembolization? World J Gastrointest Surg 2022; 14(10): 1150-1160

**URL:** https://www.wjgnet.com/1948-9366/full/v14/i10/1150.htm

**DOI:** https://dx.doi.org/10.4240/wjgs.v14.i10.1150

---

**INTRODUCTION**

Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality worldwide[1]. Unfortunately, most patients with HCC are diagnosed at the advanced stage and thus lose the opportunity for surgical resection. Transcatheter arterial chemoembolization (TACE), which blocks local blood supply of cancerous lesions to induce ischemia and necrosis with a mixture of chemotherapeutic agents[2], has been performed as a palliative treatment for patients with advanced stage HCC. With TACE, the survival rate and prognosis of patients with HCC could be significantly improved[3]. However, due to hypervascular feature and possibly established new collateral circulation[4], HCC is prone to being recurrent after TACE treatment. Thus, an accurate evaluation method is essential to help guide subsequent therapeutic planning for patients with HCC after TACE in clinical practice. In addition, after TACE, there may be microscopic changes prior to morphological changes in the peritumoral liver parenchyma zone of the true progression. While, no related studies have been conducted regarding this.

Magnetic resonance imaging (MRI) has clinical potential in evaluating the effect of TACE in patients with liver cancer[5]. However, anatomical MRI has some limitations. These include the following: (1) MRI signals are easily affected by various time points and different treatment methods; (2) para-
magnetic substances, such as hemorrhage, granulation tissue, protein components, and steatosis, present high signal on T1-weighted imaging (TIWI) and may interfere with the enhancement of recurring lesions; and (3) disordered collateral circulation in TACE area can lead to false-negative diagnosis in arterial enhancement measurement.

Diffusion MRI, as a promising method of measuring the diffusion behavior of water molecules, sensitively reflects the physiological and morphological changes of tissues[6]. Diffusion-weighted imaging (DWI) has been relatively stable to different treatment methods[7] and has shown higher diagnostic performance in liver cancer after TACE than contrast-enhanced MRI[8]. However, the DWI metric apparent diffusion coefficient, derived in mono-exponential model, tends to be affected by various factors, such as macromolecule concentration, viscosity, and capillary perfusion[9]. In contrast, diffusion kurtosis imaging (DKI), a relatively novel diffusion imaging technique describing the deviations of water molecules diffusing away from Gaussian distribution, enables the precise depiction of microstructural environment[10]. With the DKI-derived parameter mean kurtosis (MK), HCC lesions can be well distinguished between the true progression and pseudo-progression groups[11]. Moreover, together with another DKI metric, mean diffusivity (MD), MK can assess the therapeutic response to TACE in HCC[12]. Although the effectiveness of both MK and MD has been validated, the remaining DKI parameters including fractional anisotropy of kurtosis (FAk), axial and radial kurtosis (KA and KR), and axial and radial diffusivity (DA and DR) have not yet been investigated for their clinical potential on HCC diagnosis after TACE. In addition, whether there are microscopic or molecular level changes in the liver parenchyma around the surviving lesion needs to be investigated.

Therefore, this study aimed to systematically explore the clinical feasibility of all DKI-derived metrics in predicting recurrence and cellular invasion of the peritumoral liver zone of HCC after TACE.

**MATERIALS AND METHODS**

**Subjects**

The local institutional review board approved this study, and each subject provided written informed consent. From January to May 2019, 76 patients (46 males vs 30 females; mean age, 55 years ± 12 years) with 82 HCC nodules were recruited in this study after receiving TACE treatment (1.4 mo ± 0.8 mo). Based on the pathological examination or the overall modified response evaluation criteria in solid tumors (mRECIST) criteria, 48 relapse/residual lesions and 34 stable and inactive lesions were divided into true progression and pseudo-progression groups, respectively. The true progression was pathologically manifested as viable tumor cells in the foci, including primary liver cancer among the incisions, necrotic material, and granulomatous inflammation. The pseudo-progression was manifested as absence of the cancer cell infiltration in the operation area, only liver cirrhosis nodules, and some fibrous necrosis components (Figure 1).

According to the mRECIST criteria proposed by the American Association for the Study of Liver Diseases and European Association for the Study of the Liver and combined clinical indications, we considered the following lesions as true progression lesions[13]: (1) Progressive disease: Target lesion diameter increased by at least 20% on enhanced imaging compared with previous examination; (2) stable disease: Target lesion did not change; (3) partial response: The sum of initial lesion diameters in all target areas was reduced by at least 30%; (4) digital subtraction angiography (DSA): Lipiodol angiography found tumor staining in the focus area; and (5) alpha-fetoprotein (AFP) was significantly increased. However, if lesions met the following criteria, they were classified into the pseudo-progression group: (1) After TACE, DSA revealed that the focus was stable (no clear tumor blood vessels, tumor staining, clear arterial-venous/portal fistula, or vein-portal fistula); (2) after follow-up for a period of time (7.8 mo ± 0.5 mo), previous foci showed no signs of recurrence (all target lesions disappeared during the arterial enhancement phase of imaging); and (3) AFP was normal.

**Imaging acquisition**

All MRI studies were performed using a 3T MRI scanner (Discovery MR750, GE, United States), with eight-channel abdomen coils employed. A respiratory-gated spin-echo echo-planar imaging DKI sequence was performed in the axial plane. The corresponding applied scan parameters were as follows: Repetition time (TR), 3333 ms; echo time (TE), 69.4 ms; slice thickness, 6 mm; slice spacing, 2.0 mm; field of view, 360 mm × 288 mm; and matrix size, 128 × 128. In addition, five b values (400, 800, 1200, 1600, and 2000 s/mm²) and 15 directions at each b value were used. The total scan time was 10 min. Conventional MRI was also performed, with the following parameters: T1WI: TR 3.7 ms, TE 1.1 ms, and slice thickness 6 mm; T2WI: TR 2319.5 ms, TE 68.0 ms, and slice thickness 6.0 mm; FS-T2WI: TR 9000.0 ms, TE 81.0 ms, and slice thickness 6.0 mm; and DWI sequence: TR 5000 ms and TE 50.8 ms. Dynamic-enhanced MRI with gadopentetate dimeglumine, captured the arterial (20 s), venous (60 s), delayed (2 min) and hepatobiliary (45-120 min) phases. Gadolinium-diethylenetriamine penta-acetic acid of 15-20 mL was injected intravenously through the back of the hand at a rate of 2 mL/s.
Figure 1 Flowchart of patient enrollment. n: Number of cases; TACE: Transcatheter arterial chemoembolization; mRECIST: Modified response evaluation criteria in solid tumors; DSA: Digital subtraction angiography.

DSA was performed under guidance on a Toshiba rotary DSA (GEIGS530, United States) machine. All patients were approached via the femoral artery and routinely underwent skin preparation, disinfection, draping, and local anesthesia in the groin area. After the artery was successfully inserted, the guide wire and catheter sheath were sequentially inserted. The Cook 5-F RH tube was introduced to select the abdominal trunk or common hepatic angiography to observe the tumor staining.

Data analysis

Two professional radiologists (Hansen and HC), with 30 and 10 years of experience in MRI assessment, respectively, independently recorded the imaging and clinical data of the true progression and pseudo-progression groups (Table 1). All acquired DKI images were examined on the workstation using vendor-supplied postprocessing software (GE AW4.6 advantage, United States). The corresponding mappings of DKI-derived parameters (i.e., MD, DA, DR, MK, KA, KR, and FAk) were obtained. The two radiologists independently selected the regions of interest (ROIs) for TACE-treated area, peritumoral area (distance < 2 cm to the tumor), and long-distance area (distance > 5 cm) on anatomical DKI image at $b = 0$ s/mm$^2$ and then copied them on each of the DKI-derived parametric maps (Figure 2). Each expert selected two different ROIs and calculated the average value. All chosen ROIs of a circular or oval form were selected carefully to avoid necrotic area. Considering the inter-subject variation, all obtained values were standardized based on the following formulas: $\text{Std}_{\text{pseudo-progression}} = \text{ROI (pseudo-progression lesion)}/\text{ROI (normal parenchyma)}$ and $\text{Std}_{\text{progression}} = \text{ROI (progression lesion)}/\text{ROI (normal parenchyma)}$.

Statistical analysis

All statistical analyses were performed using the Statistical Package for the Social Sciences version 22.0 statistical software. Intra-class correlation coefficient (ICC) analysis was performed to evaluate the inter-agreement of DKI parameter assessment by the two professional experts. The non-parametric $U$ test and receiver operating characteristic (ROC) curve analysis were used to evaluate the differences and prediction performance of the DKI-derived parameters. The independent sample $t$-test was used to compare all DKI metrics in the peritumoral zone (distance < 2 cm) and the far-tumoral zone (distance > 5 cm) of the true progression group. $P < 0.05$ was considered statistically significant.
Table 1 Summary of clinical data of patients in true and pseudo-progressing groups

| Characteristic                  | All cases (n = 82) | True group (n = 48) | Pseudo-group (n = 34) | P value |
|--------------------------------|--------------------|---------------------|-----------------------|---------|
| Age range (yr)                 | 55 ± 12            | 50 ± 16             | 53 ± 14               | 0.745   |
| Male/female (n)                | 46/30              | 26/18               | 20/12                 | 0.402   |
| AFP (ng/mL) (+/-)              | 49/33              | 47/1                | 2/32                  | 0.001   |
| Tumor size (cm)                | 4.0 ± 1.8          | 4.2 ± 1.6           | 2.7 ± 1.3             | 0.142   |
| Enhancement (+/-)              | 50/32              | 46/2                | 4/30                  | 0.006   |
| DSA (+/-)                      | 42/27              | 42/2                | 0/25                  | < 0.010 |
| Resection (+/-)                | 10                 | 9                   | 1                     | -       |
| TACE times (single/repeated)   | 26/56              | 4/44                | 22/12                 | < 0.011 |
| Follow-up for > 6 mo (+/-)     | 39/33              | 39/0                | 0/33                  | < 0.001 |

AFP: Alpha-fetoprotein; DSA: Digital subtraction angiography; TACE: Transcatheter arterial chemoembolization.

Figure 2 Representative maps of transcatheter arterial chemoembolization-treated and recurrent hepatocellular carcinoma foci. The patient was a 46-year-old man with transcatheter arterial chemoembolization-treated and recurrent hepatocellular carcinoma foci. A: Diffusion map with $b = 0 \text{ s/mm}^2$; B: Maps of mean kurtosis (MK); C: Maps of mean diffusivity (MD); D: Maps of radial kurtosis (KR); E: Maps of axial kurtosis (KA); F: Maps of axial diffusivity (DA); G: Maps of radial diffusivity (DR); H: Maps of anisotropy coefficient of kurtosis (FAk). In the first map (A), the region of interest (ROI) (1) corresponds to the arrow pointing to a new lesion. The peritumoral zone (distance < 2 cm) refers to ROI (2) (red circle), and far-tumoral zone (diameter > 5 cm) refers to ROI (3) (green square).

RESULTS

Clinical data analysis
Clinical data, including age, gender, and tumor-related characteristics, of patients in the true progression and pseudo-progression groups are summarized in Table 1. There were significantly more patients in the true progression group than in the pseudo-progression group. Moreover, the true progression group had higher serum AFP level (> 200 ng/mL) ($P < 0.05$) than the pseudo-progression group. In addition, significantly greater proportions of patients in the progression group showed typical enhancement (95.8%) and more or less tumor staining in lipiodol angiography (95.5%). In contrast, tumor size and age range were similar between the two groups ($P > 0.05$). Among the 48 nodules in the progression group, 44 received repeated TACE, and the mean number of TACE sessions per nodule was 1-3. Four nodules underwent only a single course of TACE.

Inter-observer agreement analysis
As shown in Table 2, ICC analysis was utilised by two radiologists to assess the inter-agreement of each DKI parameter measurement on the TACE-treated region, peritumoral zone, and far-tumoral zone,
Table 2 Evaluation of inter-observer agreement using intra-class correlation coefficient analysis

|       | MK  | MD  | KA  | KR  | DA  | DR  | FAK |
|-------|-----|-----|-----|-----|-----|-----|-----|
| ROI (T) | 0.86 | 0.85 | 0.80 | 0.83 | 0.76 | 0.78 | 0.62 |
| ROI (N)  | 0.79 | 0.74 | 0.71 | 0.76 | 0.72 | 0.75 | 0.54 |
| ROI (F)  | 0.70 | 0.73 | 0.69 | 0.68 | 0.64 | 0.70 | 0.50 |

FAk: Anisotropy coefficient of kurtosis; ROC: Receiver operating characteristic curve; MD: Mean diffusivity; MK: Mean kurtosis; KA: Axial kurtosis; KR: Radial kurtosis; DA: Axial diffusivity; DR: Radial diffusivity.

Table 3 Diffusion kurtosis imaging derived metrics in true and pseudo-progressing lesions

|       | MK  | MD  | KR  | KA  | DR  | DA  | FAK |
|-------|-----|-----|-----|-----|-----|-----|-----|
| N     | 0.60 ± 0.15 | 1.90 ± 0.65 | 0.55 ± 0.16 | 0.60 ± 0.13 | 1.88 ± 0.55 | 2.20 ± 0.63 | 0.10 ± 0.09 |
| Y     | 0.71 ± 0.24 | 1.60 ± 0.45 | 0.65 ± 0.29 | 0.70 ± 0.15 | 1.4 ± 0.38 | 2.10 ± 0.60 | 0.32 ± 0.22 |
| Std-N | 0.68 ± 0.27 | 1.89 ± 0.58 | 0.70 ± 0.31 | 0.61 ± 0.16 | 2.01 ± 0.54 | 1.60 ± 0.42 | 0.54 ± 0.32 |
| Std-Y | 0.81 ± 0.23 | 0.91 ± 0.18 | 0.75 ± 0.24 | 1.05 ± 0.20 | 0.88 ± 0.22 | 0.92 ± 0.22 | 1.07 ± 0.78 |
| P value | 0.270 | 0.009 | 0.679 | 0.000 | 0.003 | 0.000 | 0.000 |

N = pseudo-progressing group; Y = true progressing group. FAk: Anisotropy coefficient of kurtosis; MD: Mean diffusivity; MK: Mean kurtosis; KA: Axial kurtosis; KR: Radial kurtosis; DA: Axial diffusivity; DR: Radial diffusivity.

DISCUSSION

In this study, we explored the prediction performance of DKI for recurrence and cellular invasion of the peritumoral liver zone of HCC after TACE and further investigated the characteristics of the DKI-derived metrics between the true progression and pseudo-progression groups. Considering the high data consistency between the two experts, we found that most DKI metrics, including MD, DA, DR, and FAk, showed statistically different values between the true progression and pseudo-progression groups (P < 0.05). Moreover, for the true progression group, except the metrics MK and KR, all other parameters of the peritumoral liver zone (distance < 2 cm) were significantly different from those of the far-tumoral liver parenchyma (distance > 5 cm). Therefore, we concluded that DKI with derived...
Cao X et al. Predictive function of DKI after TACE

Figure 3 Receiver operating characteristic curves of diffusion kurtosis imaging metric in predicting recurrence. AUC value greater than 0.7 indicates a higher diagnostic value. A: Mean diffusivity; B: Mean kurtosis; C: Anisotropy coefficient of kurtosis; D: Axial kurtosis; E: Radial kurtosis; F: Axial diffusivity; G: Radial diffusivity; FAk: Anisotropy coefficient of kurtosis; ROC: Receiver operating characteristic curve; MD: Mean diffusivity; MK: Mean kurtosis; KA: Axial kurtosis; KR: Radial kurtosis; DA: Axial diffusivity; DR: Radial diffusivity.

Functional metrics showed advantages in assessing the therapeutic response of HCC to TACE and also provided robust performance in evaluating peritumoral zone invasion.

Except for FAk, especially in ROI (F) (far-tumoral zone, distance > 5 cm), all other DKI metrics showed excellent consistency measured by two professional experts. FAk has been shown to have a significant benefit in the central nervous system, where the nerve fibre structure exhibits full fractional anisotropy [14]. Nevertheless, the fibre structure in the liver lacks a defined fractional anisotropy, making it difficult to identify the specificity of FAk. Furthermore, Nasu et al [15] established the idea of "pseudo-fractional anisotropy artefact of the liver", which asserts that manual selection of ROI (F) is inherently subjective and can be influenced by heartbeat and breathing artifact. This artefact might be another explanation for low consistency of FAk.

Important findings in this study were that DKI parameters, including MD, DA, DR, KA, and FAk, showed statistical differences between the true progression and pseudo-progression groups (P < 0.05). MD, DA, and DR values of pseudo-progression lesions were higher than those of true progression lesions, whereas KA and FAk values were higher in true progression lesions than in pseudo-progression lesions. Yuan et al [11] showed significant potential of DKI in assessing the therapeutic response of HCC.

DOI: 10.4240/wjgs.v14.i10.1150 Copyright ©The Author(s) 2022.
to TACE. Thus, they believed that MK is an effective biomarker in the assessment of HCC progression after TACE. This conclusion, however, is not fully consistent with our results. Compared with the pseudo-progression group with inactive foci after TACE, the normalized MK value of the true progression group with residual/recurrent foci was not higher. Since MK can reflect the complexity and density of tissues\[16\], high cell density usually shows high MK value. We hypothesized that after TACE, foci cells are swelling and experience degeneration or necrosis, while leads to a decreased cell density. Moreover, some low-activity tumor cells have been severely damaged in structure, but still retain the ability to metastasize and recur. This type of condition cannot be effectively screened out based on the characteristics of tissue density, leading to the absence of statistical difference of the MK value between the true progression and pseudo-progression groups. It is worth mentioning that KA in this study revealed certain sensitivity in assessing tumor recurrence. Follow-up studies should be further conducted to explore the underlying mechanism.

Additionally, the clinical potential of DKI in determining the invasion of peritumoral zone of the residual foci for the true progression group was assessed. We discovered that diffusion metrics (DA and DR) differed considerably between the far-tumoral zone (distance > 5 cm) and the peritumoral zone (distance < 2 cm). The peritumoral zone (distance < 2 cm) had lower DA and DR values than the far-tumoral zone (distance > 5 cm), indicating that microenvironmental alterations may occur in the peritumoral zone, which is close to residual/recurrent foci and may be sensitive in representing cancer cell infiltration. However, only KA revealed a larger value in the peritumoral zone than the far-tumoral zone among the three kurtosis coefficients (MK, KR, and KA).

Despite the fact that a variety of DKI implementations have investigated the correlations of MK and MD with fibrosis or liver function[17-20], no similar DKI findings have been published in these studies. Yoshimaru et al[17] investigated the relationship between MK and Child-Pugh score in 79 patients with varying degrees of hepatic decompensation and found a minor correlation. In comparison, Goshima et al
investigated the relationship between MK and Child-Pugh score but found no association. There was also disagreement about whether MK or MD had a superior diagnostic effectiveness for liver fibrosis. In another study, Hu et al. concluded that MD correlated strongly with the degrees of liver fibrosis, and the parameter MK may provide complementary information. In contrast, Li et al. claimed that MK could best predict the liver fibrosis stage. In this study, we did not analyze the relationship between DKI parameters and liver fibrosis or function. However, the MD value of the liver parenchyma (peritumoral and far-tumoral zones) was lower in the true progression group than in the pseudo-progression group. Moreover, the MK value did not show any difference between the two groups. The results obtained in this study were more inclined to the view that MD has a higher sensitivity to detect the degree of fibrosis. We thus hypothesized that poor liver function and high grade of liver fibrosis may lead to poor prognosis and high recurrence rate.

There are some limitations in the present study. First, manual selection of active ROIs is inevitably subjective. According to the results of dynamic enhancement and DSA imaging, independent measurement by two experienced radiologists can minimize measurement errors. Second, DKI with 5 b values and 15 directions per b value currently takes a long time of 10 min for imaging. Third, each patient showed different fibrosis state and liver function. To minimize this effect, we selected the liver parenchyma far away from the focus area for standardization. Fourth, there was a lack of pathological examination of tumor changes before and after TACE treatment. Further studies with more pathologically confirmed cases are required to be conducted. Fifth, it was difficult to obtain the histological results for each lesion after TACE. Therefore, no pathological support could determine whether the surrounding liver parenchyma was invaded. Relevant pathological study is requested to further explore the relationship among DKI parameters, liver fibrosis, and peripheral infiltration.

CONCLUSION

In conclusion, DKI metrics (MD, DA, DR, KA, and FAk) have been demonstrated with robust performance in predicting the therapeutic response of HCC to TACE and evaluating cellular invasion of the peritumoral zone.

ARTICLE HIGHLIGHTS

Research background

Transcatheter arterial chemoembolization (TACE) has been used to treat patients with hepatocellular carcinoma (HCC) as a palliative therapy. Nevertheless, HCC is prone to recur after TACE. Traditional anatomical MRI has certain limitations in assessing recurrence. Diffusion kurtosis imaging (DKI) provides a detailed depiction of the microstructural environment. Whether DKI-derived metrics can provide clinical feasibility in predicting HCC recurrence and cellular invasion of the peritumoral liver zone after TACE remains to be a concern.

Research motivation

To investigate the clinical use of DKI in predicting recurrence and cellular invasion of HCC in the peritumoral liver zone after TACE.

Research objectives

In this study, 76 patients with 82 hepatic cancer nodules were enrolled and underwent DKI after TACE. Forty-eight and 34 nodules were divided into two groups: True progression and pseudo-progression, respectively.

Research methods

DKI-derived metric maps were used to assess the TACE-treated area, peritumoral liver zone, and far-tumoral zone. To compare the prediction performance of each DKI metric between the true progression and pseudo-progression groups, the non-parametric U test and receiver operating characteristic curve (ROC) analysis were performed. The independent t-test was utilized to compare each DKI metric between the peritumoral and far-tumoral zones in the true progression group.

Research results

DKI metrics, including mean diffusivity (MD), axial diffusivity (DA), radial diffusivity (DR), axial kurtosis (KA), and anisotropy fraction of kurtosis (Fak), exhibited significantly different values between the true progression and pseudo-progression groups, respectively (P < 0.05). Furthermore, the peritumoral zone had substantially different DA, DR, KA, and Fak values than the far-tumoral zone in the true progression group. Additionally, MD values of the liver parenchyma (peritumoral and far-
tumoral zones) were substantially lower in the true progression group compared to the pseudo-progression group ($P < 0.05$).

**Research conclusions**
DKI has been shown to predict the therapeutic response of HCC to TACE with high accuracy. Furthermore, DKI may indicate cellular invasion of the peritumoral zone by molecular diffusion-restricted change.

**Research perspectives**
This study systematically investigated the clinical feasibility of all DKI-derived metrics in predicting recurrence and cellular invasion of the peritumoral liver zone of HCC after TACE, providing an accurate evaluation method to help guide subsequent therapeutic planning in clinical practice for patients with HCC after TACE.

**FOOTNOTES**

**Author contributions:** Cao X and Wang JY designed and performed the research, and wrote the paper; Shi H designed the research and supervised the report; Zheng YX, Ge YP, and Cheng HC contributed to the analysis; Dou WQ, Zhao XY, and Geng DY provided clinical advice.

**Supported by** the Greater Bay Area Institute of Precision Medicine, No. KCH2310094; Shanghai Sailing Program, No. 22YF140500; Research Startup Fund of Huashan Hospital Fudan University, No. 2021QD035; and Clinical Research Plan of SHDC, No. SHDC2020CR3020A.

**Institutional review board statement:** The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board of Huashan Hospital and First Affiliated Hospital of Shandong First Medical University.

**Conflict-of-interest statement:** The authors declare no conflicts of interest for this article.

**Data sharing statement:** The data presented in this study are available on request from the corresponding author. The data are not publicly available due to protecting patient privacy.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Country/Territory of origin:** China

**ORCID number:** Xin Cao 0000-0003-3839-3076; Wei-Qiang Dou 0000-0003-0056-2014; Dao-Ying Geng 0000-0002-3585-6883; Jun-Ying Wang 0000-0003-3839-3207.

**S-Editor:** Chen YL
**L-Editor:** Wang TQ
**P-Editor:** Zhao S

**REFERENCES**

1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. *J Hepatol* 2018; 69: 182-236 [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019]

2. Rognoni C, Ciani O, Sommariva S, Facciourusso A, Taricone R, Bhouri S, Mazzafferio V. Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses. *Oncotarget* 2016; 7: 72343-72355 [PMID: 27379537 DOI: 10.18632/oncotarget.11644]

3. Sacco R, Bertini M, Petruzzi P, Bertoni M, Bargellini I, Bresci G, Federici G, Gambardella L, Metrangolo S, Parisi G, Romano A, Scaramuzzino A, Tamino E, Silvestri A, Altomare E, Vignali C, Capria A. Clinical impact of selective transarterial chemoembolization on hepatocellular carcinoma: a cohort study. *World J Gastroenterol* 2009; 15: 1843-1848 [PMID: 19370751 DOI: 10.3748/wjg.15.1843]

4. Ramsey DE, Geschwind JD. Chemoembolization of hepatocellular carcinoma—what to tell the skeptics: review and meta-analysis. *Tech Vasc Interv Radiol* 2002; 5: 122-126 [PMID: 12524642 DOI: 10.1053/tvir.2002.36418]

5. Yu JS, Kim JH, Chung JJ, Kim KW. Added value of diffusion-weighted imaging in the MRI assessment of perilesional tumor recurrence after chemoembolization of hepatocellular carcinomas. *J Magn Reson Imaging* 2009; 30: 153-160 [PMID:
Cao X et al. Predictive function of DKI after TACE

19557734 DOI: 10.1002/jmri.21818

6 Labeur TA, Runge JH, Klompenhouwer EG, Klümpen HJ, Takkenberg RB, van Delden OM. Diffusion-weighted imaging of hepatocellular carcinoma before and after transarterial chemoembolization: role in survival prediction and response evaluation. *Abdom Radiol (NY)* 2019; 44: 2740-2750 [PMID: 31069479 DOI: 10.1007/s00261-019-02030-2]

7 Yang K, Zhang XM, Yang L, Xu H, Peng J. Advanced imaging techniques in the therapeutic response of transarterial chemoembolization for hepatocellular carcinoma. *World J Gastroenterol* 2016; 22: 4833-4847 DOI: 10.3748/wjg.v22.i20.4835

8 Kamel IR, Bluemke DA, Ramsey D, Abuseder A, Torbenson M, Eng J, Szarf G, Geschwind JF. Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. *AJR Am J Roentgenol* 2003; 181: 708-710 [PMID: 12933464 DOI: 10.2214/ajr.181.3.1810708]

9 Taouli B, Tolia AJ, Losada M, Babb JS, Chan ES, Bannan MA, Tobias H. Diffusion-weighted MRI for quantification of liver fibrosis: preliminary experience. *AJR Am J Roentgenol* 2007; 189: 799-806 [PMID: 17885048 DOI: 10.2214/AJR.07.2086]

10 Wang J, Dou W, Shi H, He X, Wang H, Ge Y, Cheng H. Diffusion kurtosis imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. *MAGMA* 2020; 33: 877-883 [PMID: 32377906 DOI: 10.1007/s10334-020-00846-4]

11 Yuan ZG, Wang ZY, Xia MY, Li FZ, Li Y, Shen Z, Wang XZ. Diffusion Kurtosis Imaging for Assessing the Therapeutic Response of Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma. *J Cancer* 2020; 11: 2339-2347 [PMID: 32127960 DOI: 10.7150/jca.32491]

12 Luo X, Li Y, Shang Q, Liu H, Song L. Role of Diffusional Kurtosis Imaging in Evaluating the Efficacy of Transcatheter Arterial Chemoembolization in Patients with Liver Cancer. *Cancer Biother Radiopharm* 2019; 34: 614-620 [PMID: 31560562 DOI: 10.1089/cbr.2019.2878]

13 Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. *Semin Liver Dis* 2010; 30: 52-60 [PMID: 20175033 DOI: 10.1055/s-0030-1247132]

14 Zhuo J, Keledjian K, Xu S, Pampori A, Gerardich V, Simard JM, Gallapalli RP. Changes in Diffusion Kurtosis Imaging and Magnetic Resonance Spectroscopy in a Direct Cranial Blast Traumatic Brain Injury (dc-bTBI) Model. *PLoS One* 2015; 10: e0136151 [PMID: 26301778 DOI: 10.1371/journal.pone.0136151]

15 Nasu K, Kuroki Y, Fuji H, Minami M. Hepatic pseudo-anisotropy: a specific artifact in hepatic diffusion-weighted images obtained with respiratory triggering. *MAGMA* 2007; 20: 205-211 [PMID: 17964349 DOI: 10.1007/s10334-007-0084-0]

16 Steven AJ, Zhuo J, Melhem ER. Diffusion kurtosis imaging: an emerging technique for evaluating the microstructural environment of the brain. *AJR Am J Roentgenol* 2014; 202: W26-W33 [PMID: 24370162 DOI: 10.2214/AJR.13.11365]

17 Yoshimaru D, Takatsu Y, Suzuki Y, Miyati T, Hamada Y, Funaki A, Tabata A, Maruyama C, Shimada M, Tobar M, Nishino T. Diffusion kurtosis imaging in the assessment of liver function: Its potential as an effective predictor of liver function. *Br J Radiol* 2019; 92: 20170608 [PMID: 30358410 DOI: 10.1259/bjr.20170608]

18 Goshima S, Kanematsu M, Noda Y, Kondo H, Watanabe H, Bae KT. Diffusion kurtosis imaging to assess response to treatment in hypervascular hepatocellular carcinoma. *AJR Am J Roentgenol* 2015; 204: W543-W549 [PMID: 25905960 DOI: 10.2214/AJR.14.13235]

19 Hu G, Liang W, Wu M, Chan Q, Li Y, Xu J, Luo L, Quan X. Staging of rat liver fibrosis using monoexponential, stretched exponential and diffusion kurtosis models with diffusion weighted imaging- magnetic resonance. *Oncotarget* 2018; 9: 2357-2366 [PMID: 29416777 DOI: 10.18632/oncotarget.23413]

20 Li J, Wang D, Chen TW, Xie F, Li R, Zhang XM, Jing ZQ, Yang JQ, Ou J, Cao JM. Magnetic Resonance Diffusion Kurtosis Imaging for Evaluating Stage of Liver Fibrosis in a Rabbit Model. *Acad Radiol* 2019; 26: e90-e97 [PMID: 30072289 DOI: 10.1016/j.acra.2018.06.018]
